Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 3001–3050 of 75328
The Company has appointed its President, Robin L. Oliver, to serve as principal executive officer on an interim basis.
On April 30, 2026, Thomas G. Zernick retired as Chief Executive Officer, principal executive officer, and a director of the Company.
Daniel Hennessy resigned from the Board and the Company's other committees effective as of April 29, 2026.
On April 29, 2026, the Board, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed John Hewitt to fill the vacancy created by Mr. Hennessy's resignation, effective April 29, 2026.
FMC Corporation (the “ Company ”) announced the passing of Dirk A. Kempthorne, a member of our board of directors (the “ Board ”) since 2009.
Mark Griffin, Executive Vice President, Security Solutions, Mark Bendza, Executive Vice President and Chief Financial Officer, and Hutch Robbins, Executive Vice President and General Counsel, under the oversight of and reporting to the Company’s Board of Directors, have assumed the responsibilities of the Chief Executive Officer on an interim basis.
Mark Griffin, Executive Vice President, Security Solutions, Mark Bendza, Executive Vice President and Chief Financial Officer, and Hutch Robbins, Executive Vice President and General Counsel, under the oversight of and reporting to the Company’s Board of Directors, have assumed the responsibilities of the Chief Executive Officer on an interim basis.
Mark Griffin, Executive Vice President, Security Solutions, Mark Bendza, Executive Vice President and Chief Financial Officer, and Hutch Robbins, Executive Vice President and General Counsel, under the oversight of and reporting to the Company’s Board of Directors, have assumed the responsibilities of the Chief Executive Officer on an interim basis.
John B. Wood, the Company’s President, Chief Executive Officer and Chairman of the Board, is taking a medical leave of absence.
Fred Schaufeld has been appointed by the Board of Directors to serve as its Chairman on an interim basis effective immediately.
Concurrently, Charles “Skip” R. Hageboeck transitioned from the role of President of the Bank, and will remain the Chief Executive Officer of the Bank and the President and Chief Executive Officer of the Company.
Michael “Tim” T. Quinlan, Jr., age 57, the Company’s current Executive Vice President, Retail Banking, will assume the role of President of City National Bank of West Virginia (the “Bank”) effective as of the close of business on April 29, 2026 (the “Effective Date”).
On April 27, 2026, Patrick J. Jermain, the Executive Vice President and Chief Financial Officer of Plexus Corp. ("Plexus" or the "Company"), informed the Company of his intent to retire from his employment with the Company at midnight on July 31, 2026 (the "Retirement Date").
On May 11, 2026, in accordance with the Company’s succession plan, David Abuhl will assume the role of Senior Vice President, Chief Financial Officer and principal financial and accounting officer.
Suketu Upadhyay informed the board of directors (the "Board") of Vertex Pharmaceuticals Incorporated (the "Company") of his decision not to stand for re-election as a director of the Company at the Company’s 2026 annual meeting of shareholders (the "2026 Annual Meeting").
the board of directors of each of the Company and Hawthorn Bank increased their respective sizes by one member, and appointed Grant T. Burcham to serve on both the Company's and Hawthorn Bank's board of directors to fill such newly created vacancies, in each case, effective April 29, 2026.
Paul Adams, Kirk S. Hachigian and Larry A. Lawson were appointed to the board of directors of the Company (the “Board”).
Paul Adams, Kirk S. Hachigian and Larry A. Lawson were appointed to the board of directors of the Company (the “Board”).
Paul Adams, Kirk S. Hachigian and Larry A. Lawson were appointed to the board of directors of the Company (the “Board”).
On April 24, 2026, the board of directors (the “Board”) of Forward Air Corporation (the “Company”) received notice from Charles L. Anderson and Robert L. Edwards, Jr. that each will not be standing for re-election at the Company’s annual meeting of stockholders to be held on June 17, 2026 (the “2026 Annual Meeting”).
On April 24, 2026, the board of directors (the “Board”) of Forward Air Corporation (the “Company”) received notice from Charles L. Anderson and Robert L. Edwards, Jr. that each will not be standing for re-election at the Company’s annual meeting of stockholders to be held on June 17, 2026 (the “2026 Annual Meeting”).
On April 23, 2026, the Company’s Board of Directors appointed Mr. Leonardo Contreras Lerdo de Tejada as Chief Executive Officer of the Company.
On April 13, 2026, Southern Copper Corporation (the "Company") announced with deep regret the unexpected passing of Oscar Gonzalez Rocha, the Company’s President, Chief Executive Officer, and Board member.
On April 24, 2026, both William R. Jellison, a Class I member of the Board of Directors (the "Board") of the Company, and Glenn R. Larsen, Ph.D., a Class II member of the Board, notified the Board of their resignation from the Board, including from all committees on which each serves effective as of the Company's 2026 annual meeting of stockholders (the "2026 Annual Meeting").
On April 24, 2026, both William R. Jellison, a Class I member of the Board of Directors (the "Board") of the Company, and Glenn R. Larsen, Ph.D., a Class II member of the Board, notified the Board of their resignation from the Board, including from all committees on which each serves effective as of the Company's 2026 annual meeting of stockholders (the "2026 Annual Meeting").
Effective April 24, 2026, the Board of Directors of the Company (the "Board") appointed Marc James to serve as a Class II Director of the Board for the remainder of the term of Class II Directors of the Board, expiring at the 2026 Annual Meeting of Shareholders of the Company.
Effective July 1, 2026, Matthew K. Smith will become Chief Executive Officer and President of the Company and its subsidiary, First Mid Bank & Trust, N.A., and will be appointed to the Company’s Board of Directors (the “Board”).
In connection with the succession plan, Joseph R. Dively will transition from Chief Executive Officer to Executive Chair of the Company and remain Chairman of the Board.
Eli Wallace, Ph.D. resigned from his position as a member of the Company’s Board of Directors and as a Class III director, and was succeeded by Pedro J. Beltran, Ph.D. in these positions and as the Company’s President and Chief Executive Officer, effective on April 20, 2026.
Eli Wallace, Ph.D. resigned from his position as a member of the Company’s Board of Directors and as a Class III director, and was succeeded by Pedro J. Beltran, Ph.D. in these positions and as the Company’s President and Chief Executive Officer, effective on April 20, 2026.
Eli Wallace, Ph.D. resigned from his position as a member of the Company’s Board of Directors and as a Class III director, and was succeeded by Pedro J. Beltran, Ph.D. in these positions and as the Company’s President and Chief Executive Officer, effective on April 20, 2026.
Eli Wallace, Ph.D. resigned from his position as a member of the Company’s Board of Directors and as a Class III director, and was succeeded by Pedro J. Beltran, Ph.D. in these positions and as the Company’s President and Chief Executive Officer, effective on April 20, 2026.
The Board has nominated Martin Babler and Troy Cox as Class I director nominees to replace Dr. Malenka and Dr. Trenkle.
On April 23, 2026, Robert Malenka, M.D., Ph.D., and Jim Trenkle, Ph.D., notified the Board of Directors (the "Board") of MapLight Therapeutics, Inc. (the "Company") of their respective decisions not to stand for reelection at the Company’s Annual Meeting of Stockholders to be held on June 23, 2026.
The Board has nominated Martin Babler and Troy Cox as Class I director nominees to replace Dr. Malenka and Dr. Trenkle.
On April 23, 2026, Robert Malenka, M.D., Ph.D., and Jim Trenkle, Ph.D., notified the Board of Directors (the "Board") of MapLight Therapeutics, Inc. (the "Company") of their respective decisions not to stand for reelection at the Company’s Annual Meeting of Stockholders to be held on June 23, 2026.
the Board appointed Dr. Prakash Raman to the Board as a Class II director, effective April 28, 2026
In connection with the appointment, John Allen will cease serving as the Company’s Interim Chief Financial officer, effective as of the same date, and will continue to serve as the Company’s Vice President, Accounting and Chief Accounting Officer.
The Board of Directors (the “Board”) of Rambus Inc. (“Rambus” or the “Company”) has appointed Sumeet Gagneja as the Senior Vice President and Chief Financial Officer of the Company, effective April 29, 2026, reporting to Luc Seraphin, Chief Executive Officer of the Company.
On April 27, 2026, in connection with the IPO, William Sherman was appointed to the board of directors of the Company (the “ Board ”) effective April 28, 2026.
Sam Eaton notified Yelp Inc. (the “Company”) of his decision to step down from his position as Chief Technology Officer, effective June 30, 2026
Lazar will succeed Arturo Rodriguez
the Board increased the authorized number of directors to five and appointed Lazar to the Board to fill the vacancy created by such increase, effective immediately
the Board agreed to appoint Lazar as the sole Chief Executive Officer of the Company promptly following the Second SPA Closing
Bharat Vasan notified the Board of Directors of Starco Brands, Inc. (the “Company”), that he resigns from the Board of Directors, effective April 27, 2026.
Effective April 29, 2026, the Company and TWNP each appointed Keshav Lall as its interim Chief Executive Officer, filling in for the former Chief Executive Officer who remains on a leave of absence pursuant to the Amended and Restated Stipulation and Agreed Order Regarding Mediated Agreement [Docket No. 472].
On April 23, 2026, Neeraj Agrawal notified the Board that he will not stand for re-election as a Class II director of the Company at the 2026 Annual Meeting.
On April 23, 2026, Yvette Kanouff notified the board of directors (the “Board”) of Sprinklr, Inc. (the “Company”) that she will not stand for re-election as a Class II director of the Company at the Company’s 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”).
On April 26, 2026, Diane Bryant resigned as a member of the Board of Directors of Jacobs Solutions Inc. (the “Company”).
On April 24, 2026, Jodi Devlin provided notice to TriSalus Life Sciences, Inc. (the “Company”) of her intention to retire from her role as Chief of Clinical Operations, effective October 1, 2026.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.